At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
Melatonin +1 moredrug
Likely dose
Melatonin 24mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study
In Brief
A Phase 2 clinical trial evaluating Melatonin and Placebo for Hypertension. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The purpose of this study is to test the effect of oral melatonin supplementation (24 mg per night for 4 weeks) on nighttime blood pressure in African Americans with a history of elevated nighttime blood pressure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2010
Enrollment StartJun 2010
Primary CompletionSep 2013
Study CompletionSep 2014
TodayJul 2026
First PostedMay 3, 2010
Enrollment StartJun 1, 2010
Primary CompletionSep 1, 2013
Study CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 16.2 years ago
Interventions
Melatonindrug
Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 24mg of time release melatonin pills (3 x 8mg) to be taken orally at night for 4 weeks.
Placebodrug
Subjects will receive placebo pills (3 pills) to be taken orally once per night for 4 weeks.